Search results

Selected filters:

North America
Law & Policy

Article type

Topic

Sector

Jurisdictions

567 results found for your search

Sort options
19 October 2019

Why the Red Hat tail will end up wagging the Big Blue dog

IBM's decision to purchase the open source powerhouse was a $34 billion bet on the future and from an IP perspective something has to give

15 October 2019

As PTAB settlement rate ticks up some see evidence of a maturing review system

Data shows both pre- and post-institution agreements at highest levels since 2014 and comes against backdrop of dramatic fall in new IPR filings

15 October 2019

California’s first-of-a-kind reverse payment law is a further obstacle to litigation settlements

Pharma patent litigation settlements involving the transfer of “anything of value” to the generic are now presumed anti-competitive under Golden State law

10 October 2019

Patent term adjustments in the US are readjusted, again

Two recent Federal Circuit decisions have shed further light on a highly litigated area of biopharma patent law

08 October 2019

New wave of company blacklistings in the US will accelerate Chinese tech’s inward turn

Eight Chinese entities – including leaders in AI, facial recognition and data forensics - added to Bureau of Industrial Security entity list

07 October 2019

Judge Moore's “validity goulash” comments cause Congressman to wade into eligibility debate

Representative Doug Collins claims CAFC propeller shaft patent decision underlines need for legislative action on 101

05 October 2019

The USPTO seeks AI expertise to change the rules of the game internally and externally

New role has the potential to deliver results that will enhance internal processes, improve quality, lower costs and help recover lost US influence in the international IP arena

02 October 2019

New PTAB cases drop dramatically in latest sign that recent changes are having an impact

Post-issuance reviews drop by over a fifth year-on-year, according to latest data, while district court litigation also continues its decline

28 September 2019

The US is gifting 5G patent leadership to others

Policy confusion and problematic court decisions mean that the shape of the IP landscape in this pivotal technology is being determined elsewhere

27 September 2019

Huawei’s FRAND strategy: move cases to China

The company wants to shift disputes to its home jurisdiction and persuade courts there to set a low, China-specific rate

26 September 2019

Allegations of sham pharma patent litigation are growing, but claimants have a mountain to climb

Akorn Inc’s failure to make its case against Allergan and Duke is a reminder that challenging life sciences patentees remains a tough task

23 September 2019

With no sign of trade war compromise, DOJ official attacks Chinese system that “encourages and rewards IP theft”

Comments by Deputy Assistant Attorney General in interview also suggests that the US will continue to take a more proactive approach to policing security risks in telecoms networks  

21 September 2019

Huawei’s 5G spinoff bluff shows why export ban will hurt US tech firms

CEO Ren Zhengfei doesn’t think another company can build a business around Huawei’s 5G technology stack. Not only will the company's predicament not help US tech firms, it is actively hurting them

19 September 2019

After Congressional hearing, still no clarity over US government divide in FTC v Qualcomm

SEP owners left in the dark following Senate committee session in which antitrust chiefs Delrahim and Simons played down significance of split in agencies' views of key case

16 September 2019

Genentech dispute highlights growing importance of trade secrets for life sciences companies

Legal and commercial developments suggest that disputes over increasingly valuable biopharma know-how, proprietary information and data will increase in years to come.